Answers are grounded in this paper and cite their sources.
The Centers for Disease Control has recently reported an association between the use of oral L-tryptophan preparations and a disease marked by severe myalgia, peripheral eosinophilia, and neuromuscular and cutaneous abnormalities. They have labeled the condition eosinophilia-myalgia syndrome. We report here the clinical and histopathologic findings in 4 patients who developed an illness resembling eosinophilic fasciitis following the initiation of oral L-tryptophan supplementation.
No takes yet. Share an insight, caveat, or question.
Bulpitt et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: